Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Legend Biotech ( (LEGN) ) has issued an announcement.
On January 12, 2026, Legend Biotech reported at the J.P. Morgan Healthcare Conference that its flagship multiple myeloma therapy CARVYKTI has now been used to treat more than 10,000 clinical and commercial patients, supported by a significant global rollout to 279 sites in 14 markets and the completion of a major expansion of its Raritan, New Jersey facility, which is now the largest cell therapy manufacturing plant in the United States and can support up to 10,000 patients annually. The company highlighted strong late-stage clinical data presented in December 2025 showing durable progression-free survival and benefits from earlier-line use, recent US and EU label updates adding overall survival advantage versus standard therapies, and progress across its broader pipeline, including first-in-human results from allogeneic candidate LUCAR-G39D, opening a new Philadelphia R&D center, and dosing a first patient with a dual CD20/CD19 in vivo CAR-T, while also signaling a shift toward financial inflection with expected CARVYKTI franchise profitability in 2025, anticipated company-wide operating profit in 2026 and roughly $1.0 billion in cash and time deposits as of September 30, 2025.
The most recent analyst rating on (LEGN) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
Spark’s Take on LEGN Stock
According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.
Legend Biotech’s strong revenue growth and strategic advancements in CARVYKTI are overshadowed by significant profitability and cash flow challenges. The technical indicators suggest bearish momentum, and the valuation metrics reflect ongoing financial struggles. While the earnings call provides a positive outlook, the company’s current financial health remains a concern.
To see Spark’s full report on LEGN stock, click here.
More about Legend Biotech
Legend Biotech Corporation is a US-headquartered, standalone cell therapy company specializing in CAR-T treatments for cancer, notably CARVYKTI, a one-time therapy for relapsed or refractory multiple myeloma developed in collaboration with Johnson & Johnson. With more than 2,900 employees and a growing global footprint, the company is building an end-to-end cell therapy platform to expand patient access, enhance manufacturing capacity and advance a pipeline of innovative cell therapy modalities across oncology and immunology.
Average Trading Volume: 1,968,240
Technical Sentiment Signal: Sell
Current Market Cap: $4.25B
See more data about LEGN stock on TipRanks’ Stock Analysis page.